Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: A novel approach for the treatment of bladder cancer

Stem Cells and Development

Volumn 21, Issue 7, 2012, Pages 1097-1111

  Bitsika, Vasiliki ^a,b   Roubelakis, Maria G ^a,b   Zagoura, Dimitra ^a,b   Trohatou, Ourania ^a,b   Makridakis, Manousos ^a   Pappa, Kalliopi I ^a,b   Marini, Frank C ^c   Vlahou, Antonia ^a   Anagnou, Nicholas P ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR;

AMNION FLUID; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL EXPANSION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR MODEL;

AMNIOTIC FLUID; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DRUG DELIVERY SYSTEMS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERFERON-BETA; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEOME; RECOMBINANT PROTEINS; TUMOR BURDEN; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860183428     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0151     Document Type: Article

References (57)

1. Dinney CP, DJ McConkey, RE Millikan, X Wu, M Bar-Eli, L Adam, AM Kamat, AO Siefker-Radtke, T Tuziak, et al. (2004). Focus on bladder cancer. Cancer Cell 6:111-116.
2. Makridakis M, S Gagos, A Petrolekas, MG Roubelakis, V Bitsika, K Stravodimos, K Pavlakis, NP Anagnou, J Coleman and A Vlahou. (2009). Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics 9:287-298.
3. Sylvester RJ. (2006). Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal 6:2617-2625.
4. Crallan RA, NT Georgopoulos and J Southgate. (2006). Experimental models of human bladder carcinogenesis. Carcinogenesis 27:374-381.
5. Makridakis M, MG Roubelakis, V Bitsika, V Dimuccio, M Samiotaki, S Kossida, G Panayotou, J Coleman, G Candiano, NP Anagnou and A Vlahou. (2010). Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. J Proteome Res 9:3243-3259.
6. MakridakisMand A Vlahou. (2010). Secretome proteomics for discovery of cancer biomarkers. J Proteomics 73:2291-2305.
7. Pestka S, JA Langer, KC Zoon and CE Samuel. (1987). Interferons and their actions. Annu Rev Biochem 56:727-777.
8. Studeny M, FC Marini, RE Champlin, C Zompetta, IJ Fidler and M Andreeff. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603-3608.
9. Dong Z, G Greene, C Pettaway, CP Dinney, I Eue,W Lu, CD Bucana, MD Balbay, D Bielenberg and IJ Fidler. (1999). Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon- beta. Cancer Res 59:872-879.
10. Qin XQ, L Runkel, C Deck, C DeDios and J Barsoum. (1997). Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 17:355-367.
11. Einhorn S and D Grander. (1996). Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 16:275-281.
12. Salmon P, JY Le Cotonnec, A Galazka, A Abdul-Ahad and A Darragh. (1996). Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 16:759-764.
13. Le Page C, P Genin, MG Baines and J Hiscott. (2000). Interferon activation and innate immunity. Rev Immunogenet 2:374-386.
14. Chen X, X Lin, J Zhao, W Shi, H Zhang, Y Wang, B Kan, L Du, B Wang, Y Wei, Y Liu and X Zhao. (2008). A tumorselective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 16:749-756.
15. Corsten MF and K Shah. (2008). Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol 9:376-384.
16. Komarova S, Y Kawakami, MA Stoff-Khalili, DT Curiel and L Pereboeva. (2006). Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 5:755-766.
17. Nakamizo A, F Marini, T Amano, A Khan, M Studeny, J Gumin, J Chen, S Hentschel, G Vecil, et al. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318.
18. Studeny M, FC Marini, JL Dembinski, C Zompetta, M Cabreira-Hansen, BN Bekele, RE Champlin and M Andreeff. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593-1603.
19. Bexell D, S Scheding and J Bengzon. (2010). Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 18:1067-1075.
20. Lee DH, Y Ahn, SU Kim, KC Wang, BK Cho, JH Phi, IH Park, PM Black, RS Carroll, J Lee and SK Kim. (2009). Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 15:4925-4934.
21. Barry FP. (2003). Biology and clinical applications of mesenchymal stem cells. Birth Defects Res C Embryo Today 69:250-256.
22. Gregory CA, DJ Prockop and JL Spees. (2005). Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res 306:330-335.
23. Pappa KI and NP Anagnou. (2009). Novel sources of fetal stem cells: where do they fit on the developmental continuum? Regen Med 4:423-433.
24. Rachakatla RS, F Marini, ML Weiss, M Tamura and D Troyer. (2007). Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther 14:828-835.
25. Rachakatla RS, MM Pyle, R Ayuzawa, SM Edwards, FC Marini, ML Weiss, M Tamura and D Troyer. (2008). Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest 26:662-670.
26. Kidd S, L Caldwell, M Dietrich, I Samudio, EL Spaeth, K Watson, Y Shi, J Abbruzzese, M Konopleva, M Andreeff and FC Marini. (2010). Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12:615-625.
27. Ren C, S Kumar, D Chanda, J Chen, JD Mountz and S Ponnazhagan. (2008). Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 26:2332-2338.
28. Spaeth E, A Klopp, J Dembinski, M Andreeff and F Marini. (2008). Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15:730-738.
29. Hall B, M Andreeff and F Marini. (2007). The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol (180):263-283.
30. In 't Anker PS, SA Scherjon, C Kleijburg-van der Keur, WA Noort, FH Claas, R Willemze, WE Fibbe and HH Kanhai. (2003). Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 102:1548-1549.
31. Tsai MS, JL Lee, YJ Chang and SM Hwang. (2004). Isolation of human multipotent mesenchymal stem cells from secondtrimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod 19:1450-1456.
32. Tsai MS, SM Hwang, YL Tsai, FC Cheng, JL Lee and YJ Chang. (2006). Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod 74:545-551.
33. Roubelakis MG, KI Pappa, V Bitsika, D Zagoura, A Vlahou, HA Papadaki, A Antsaklis and NP Anagnou. (2007). Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 16:931-952.
34. De Coppi P, G Bartsch, Jr., MM Siddiqui, T Xu, CC Santos, L Perin, G Mostoslavsky, AC Serre, EY Snyder, et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25:100-106.
35. Roubelakis MG, V Bitsika, D Zagoura, O Trohatou, KI Pappa, M Makridakis, A Antsaklis, A Vlahou and NP Anagnou. (2011). In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med. 15:1896-1913.
36. He LF, YG Wang, T Xiao, KJ Zhang, GC Li, JF Gu, L Chu, WH Tang, WS Tan and XY Liu. (2009). Suppression of cancer growth in mice by adeno-associated virus vectormediated IFN-beta expression driven by hTERT promoter. Cancer Lett 286:196-205.
37. Schiller JH, B Storer, G Bittner, JK Willson and EC Borden. (1988). Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma. J Interferon Res 8:581-589.
38. Leschot NJ, M Verjaal and PE Treffers. (1985). Risks of midtrimester amniocentesis; assessment in 3000 pregnancies. Br J Obstet Gynaecol 92:804-807.
39. Eddleman KA, FD Malone, L Sullivan, K Dukes, RL Berkowitz, Y Kharbutli, TF Porter, DA Luthy, CH Comstock, et al. (2006). Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 108:1067-1072.
40. Dull T, R Zufferey, M Kelly, RJ Mandel, M Nguyen, D Trono and L Naldini. (1998). A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
41. Zufferey R, T Dull, RJ Mandel, A Bukovsky, D Quiroz, L Naldini and D Trono. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873-9880.
42. Siapati EK, BW Bigger, J Miskin, D Chipchase, KL Parsley, K Mitrophanous, M Themis, AJ Thrasher and D Bonnet. (2005). Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells. Mol Ther 12:537-546.
43. Salmon P and D Trono. (2006). Production and titration of lentiviral vectors. Curr Protoc Neurosci Chapter 4:Unit 4 21.
44. Birnbaum T, J Roider, CJ Schankin, CS Padovan, C Schichor, R Goldbrunner and A Straube. (2007). Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 83:241-247.
45. Gutova M, J Najbauer, RT Frank, SE Kendall, A Gevorgyan, MZ Metz, M Guevorkian, M Edmiston, D Zhao, et al. (2008). Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26:1406-1413.
46. Cheng P, ZQ Gao, YH Liu and YX Xue. (2009). Plateletderived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett 451:52-56.
47. Kargiotis O, JS Rao and AP Kyritsis. (2006). Mechanisms of angiogenesis in gliomas. J Neurooncol 78:281-293.
48. Dwyer RM, SM Potter-Beirne, KA Harrington, AJ Lowery, E Hennessy, JM Murphy, FP Barry, T O'Brien and MJ Kerin. (2007). Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13:5020-5027.
49. Gao X and Z Xu. (2008). Mechanisms of action of angiogenin. Acta Biochim Biophys Sin (Shanghai) 40:619-624.
50. Gao Y, A Yao, W Zhang, S Lu, Y Yu, L Deng, A Yin, Y Xia, B Sun and X Wang. (2010). Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 29:2784-2794.
51. Yong RL, N Shinojima, J Fueyo, J Gumin, GG Vecil, FC Marini, O Bogler, M Andreeff and FF Lang. (2009). Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 69:8932-8940.
52. Mohr A, M Lyons, L Deedigan, T Harte, G Shaw, L Howard, F Barry, T O'Brien and R Zwacka. (2008). Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 12:2628-2643.
53. Zipori D. (2006). The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer Metastasis Rev 25:459-467.
54. Guillot PV, C Gotherstrom, J Chan, H Kurata and NM Fisk. (2007). Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells 25:646-654.
55. Matsuzuka T, RS Rachakatla, C Doi, DK Maurya, N Ohta, A Kawabata, MM Pyle, L Pickel, J Reischman, et al. (2010). Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer 70:28-36.
56. Parmar S and LC Platanias. (2003). Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 15:431-439.
57. Buchwalder PA, T Buclin, I Trinchard, A Munafo and J Biollaz. (2000). Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20:857-866.